



## MITHRA PHARMACEUTICALS RELEASES 2016 ANNUAL REPORT AND INVITATION TO ITS ORDINARY GENERAL SHAREHOLDERS' MEETING

**Liège, Belgium 18 April 2017** – Mithra Pharmaceuticals is pleased to announce the publication of its 2016 Annual Report and the invitation for its Ordinary General Shareholders' meeting.

### Annual Report

The Annual Report which outlines Mithra's achievements in 2016 includes the following information:

- Overview of Mithra's R&D pipeline and letter to shareholders;
- Highlights of Mithra's strategy and outlook for 2017;
- Corporate governance section;
- Financial statements and notes.

**François Fornieri, CEO Mithra Pharmaceuticals:** *"During 2016 we made substantial progress on the key programs that we believe will deliver Mithra's long-term international growth as a transformational leader in women's health. We look forward to building on this progress in the year ahead as we move closer to commercializing Estelle® and to selecting a suitable partner to further develop Donesta®. We also anticipate filing for marketing approval for our vaginal contraceptive, Myring™, in both Europe and the US in 2017."*

Mithra releases its Annual Report in English and French. In case of interpretation differences, the English version will prevail.

The report is available in English and French and can be downloaded on the website [investors.mithra.com](http://investors.mithra.com) as a PDF file.

### Ordinary General Shareholders' meeting

The Ordinary General Shareholders' meeting of Mithra Pharmaceuticals will be held on 18<sup>th</sup> May 2017 at 5:00 PM (CEST) in Liège (Belgium). Mithra Pharmaceuticals is pleased to invite its shareholders.

The notice for the Ordinary General Shareholders' meeting including a description of the formalities to participate in the Meeting is available on the website [investors.mithra.com](http://investors.mithra.com).

## Pictures

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/en/press-media>

## For more information, please contact:

### Press

#### **Julie Dessart**

Chief Communication Officer  
+32 4 349 28 22 / +32 475 86 41 75  
[press@mithra.com](mailto:press@mithra.com)

### Investor Relations

#### **François Fornieri, CEO**

+32 349 28 22

#### **Sofie Van Gijssel**

Investor Relations Officer  
+32 4 349 28 22 / +32 485 19 14 15  
[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

#### **Consilium Strategic Communications**

Jonathan Birt, Sue Stuart, Hendrik Thys  
+44 2 037 095 700  
[mithra@consilium-comms.com](mailto:mithra@consilium-comms.com)

## About Mithra

Mithra Pharmaceuticals SA (Euronext MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle<sup>®</sup>, and a next generation hormone therapy, Donesta<sup>®</sup> - are built on Mithra's unique native estrogen platform (E4). Mithra also develops and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra has an approximate headcount of 140 staff members and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

To subscribe to Mithra's newsletter, visit [investors.mithra.com](http://investors.mithra.com)